Blood Clots

How can blood clots be prevented?

Prevention is key in thrombosis or clot formation.

Arterial thrombosis

  • For arterial thrombosis, the most likely precipitating event is a plaque rupture with clot formation in the artery.
  • Minimizing the risk of vascular disease requires life-long attention to the risk factors that lead to plaque buildup and "hardening" of the arteries.
  • Blood pressure and cholesterol control, diabetes management, and refraining from smoking all minimize the risk of arterial disease.
  • Although family history is an important risk factor, one needs to be even more vigilant about the other risk factors if there is a family history of early heart attack or stroke.

Deep vein thrombosis

The main risk factor for deep vein thrombosis risks is immobilization. It is important to move around routinely so that blood can circulate in the venous system. On long trips, it is recommended to get out of the car every couple of hours and in an airplane routinely get up and stretch.

Physicians and nurses work hard at getting people moving after surgery or while in the hospital for medical conditions. The low molecular weight heparin known as enoxaparin (Lovenox) can also be used in low doses to prevent clot formation. Patients are often given tight stockings to promote blood return from the legs and prevent pooling of blood.

In patients with atrial fibrillation, warfarin (Coumadin) was traditionally used to prevent clot formation and minimize the risk of embolus and stroke. Newer medications have been developed that prevent blood clot formation similar to warfarin and have been successfully used in patients with atrial fibrillation. These medications include dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). These newer drugs have advantages of reduced susceptibility to diet and drug interactions and convenience (lack of need for routine blood testing of the international normalized ratio or INR, as is required for warfarin therapy).

An important caution was issued by the FDA about the use of dabigatran because a clinical trial in Europe (the RE-ALIGN trial)1 was recently stopped because dabigatran users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of warfarin. There was also more bleeding after valve surgery with dabigatran use than with the use of warfarin. The FDA recommends that dabigatran not be used to prevent blood clots in patients with mechanical prosthetic heart valves.

Reviewed on 7/10/2014
Blood Clots Related Articles